Xuhanmei

Dr. Hanmei Xu is a second-class professor and doctoral supervisor at China Pharmaceutical University. She leads the marine pharmacy program, directs the Jiangsu Engineering Center for the Discovery and Evaluation of Synthetic Peptide Drugs, and is a recipient of the State Council's Special Allowance. Dr. Xu is also a member of the Biotechnology Committee of the National Pharmacopoeia Commission, an innovative and entrepreneurial talent recognized by the Ministry of Science and Technology, and a national high-level talent expert.

Dr. Xu has led her teaching and research team in editing and publishing three treatises, and has authored 215 academic papers, including 83 indexed by SCI, with a total impact factor of 710.461. As an inventor, she has applied for 135 domestic and international invention patents and software copyrights, with 81 granted. Several of her new peptide drugs and related patents have been successfully transformed, with some having entered clinical research. She has also supervised and trained over 160 master's and doctoral students.

Under her leadership, the team has presided over more than 30 major national projects, including the 863 Program, National Natural Science Foundation of China projects, and significant industry collaborations. Dr. Xu has been invited to participate in numerous academic conferences, both domestically and internationally, where she has delivered congress reports.

1. Chaowei Hao, Peng Chen, Sarra Setrerrahmane, Hanmei Xu*, A Peptide-Salinomycin Conjugate with a Bystander Effect Reduces the Stemness Characteristics of Ovarian Cancer Cells and Enhances Drug Sensitivity, European Journal of Medicinal Chemistry, 2024, 276, 116701. https://doi.org/10.1016/j.ejmech.2024.116701. (IF=6)

2. Xiaowei Xu , Jian Li c , Sarra Setrerrahmane d , Juan Zhang e , Suoqin Shi b , Yahui Hu b , Dong Lin b , Hanmei Xu*, A multifunctional antibody fusion protein 57103 targeting CD24, IL-4R, and αvβ3 for treating cancer and regulating the tumor microenvironment,Biomedicine & Pharmacotherapy,2024 Jun:175:116714.doi:10.1016/j.biopha.2024.116714.(IF:7.419)

3. Mengwei Li^#, Guangxiang Liu^#, Xinrong Jin, Hongqian Guo, Sarra Setrerrahmane, Xindi Xu, Tiantian Li, Yunfei Lin, Hanmei Xu*. Micropeptide MIAC inhibits the tumor progression by interacting with AQP2 and inhibiting EREG/EGFR signaling in renal cell carcinoma, Mol Cancer. Mol Cancer 21, 181 (2022). doi: 10.1186/s12943-022-01654-1. (IF= 37.3)

4. Li, Mengwei; Chi, Xiaowei; Wang, Ying; Setrerrahmane, Sarra; Xie, Wenwei; Hanmei Xu*; Trends in insulin resistance: insights into mechanisms and therapeutic strategy，Signal transduction and targeted therapy，2022 Jul 6;7(1):216. doi: 10.1038/s41392-022-01073-0.（IF=39.3）

5. Shi, GB;Kang, XY;Dong, FY;Liu, YC;Zhu, N;Hu, YX;Hanmei Xu;Lao, XZ*;Zheng, H*;DRAMP 3.0: an enhanced comprehensive data repository of antimicrobial peptides;NUCLEIC ACIDS RESEARCH; 2022 Jan 7;50(D1):D488-D496. doi: 10.1093/nar/gkab651（IF=16.6）

6. Bai, ZK;Yang, PW;Yu, F;Li, Z;Yao, Z;Martinez, J;Li, MW;Hanmei Xu*；Combining adoptive NK cell infusion with a dopamine-releasing peptide reduces senescent cells in aged mice；CELL DEATH & DISEASE；2022 Apr 5;13(4):305.doi: 10.1038/s41419-022-04562-w.（IF=9.0）

7. Wang Y, Li M, Chen L, Bian H, Chen X, Zheng H, Yang P, Chen Q, Hanmei Xu*. Natural killer cell-derived exosomal miR-1249-3p attenuates insulin resistance and inflammation in mouse models of type 2 diabetes. Signal Transduction and Targeted Therapy. 2021;6(1):409. DOI: 10.1038/s41392-021-00805-y. (IF=39.3)

8. Meng Li, Ying Wang, Mengwei Li, Xuezhen Wu, Sarra Setrerrahmane, Hanmei Xu*. Integrins as attractive targets for cancer therapeutics, Acta Pharmaceutica Sinica B, 2021;11(9):2726-2737. DOI:  10.1016/j.apsb.2021.01.004  (IF=14.5)

9. Meng Li, Hanmei Xu*, Junzhi Wang*, Optimized functional and structural design of dual-target LMRAP, a bifunctional fusion protein with a 25-amino-acid antitumor peptide and GnRH Fc fragment, Acta Pharmaceutica Sinica B, 2020, 10(2):262-275 .DOI:  10.1016/j.apsb.2019.10.010 (IF=14.5)

10. Peiwei Yang, Ying Wang, Zheng Yao, Xinmei Gao, Chen Liu, Xinmin Wang, Heming Wu, Xu Ding, Jialiang Hu, Bingjing Lin, Qian Li, Mengwei Li, Xin Li, Xiangying Chen, Weiyan Qi, Weiguang Li, Jianpeng Xue,* and Hanmei Xu*. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide. J Am Chem Soc. 2020 Nov 4;142(44):18874-18885. doi: 10.1021/jacs.0c08538. Epub 2020 Oct 2. (IF=15.0)

11. Mengwei Li, Xu Ding, Yinan Zhang, Xin Li, Haoze Zhou, Li Yang, Yilin Li, Peiwei Yang, Xiaomin Zhang, Jialiang Hu, Edouard Nice, Heming Wu, Hanmei Xu*. Antisense oligonucleotides targeting lncRNA AC104041.1 induces antitumor activity through Wnt2B/β-catenin pathway in head and neck squamous cell carcinomas. Cell Death Dis. 2020 Aug 13;11(8):672. doi: 10.1038/s41419-020-02820-3. (IF=9.0)

12. Mengwei Li, Xin Li, Yinan Zhang, Heming Wu, Haoze Zhou, Xu Ding, Xiaomin Zhang, Xinrong Jin, Ying Wang, Xinqiang Yin, Chencheng Li, Peiwei Yang, Hanmei Xu*. Micropeptide MIAC Inhibits HNSCC Progression by Interacting with Aquaporin 2. J Am Chem Soc. 2020 Apr 8;142(14):6708-6716. doi: 10.1021/jacs.0c00706. (IF=15.0) 

13. Ying Wang, Jiqiang Lu, Lin Chen, Huan Bian, Jialiang Hu, Dongping Li, Chunlei Xia, Hanmei Xu*. Tumor-Derived EV-Encapsulated miR-181b-5p Induces Angiogenesis to Foster Tumorigenesis and Metastasis of ESCC. Mol Ther Nucleic Acids. 2020 Jun 5;20:421-437. doi: 10.1016/j.omtn.2020.03.002. (IF=8.8) 

14. Ying Wang, Dongping Li, Jiqiang Lu, Lin Chen, Shengnan Zhang, Weiyan Qi, Weiguang Li, Hanmei Xu*. Long noncoding RNA TTN-AS1 facilitates tumorigenesis and metastasis by maintaining TTN expression in skin cutaneous melanoma. Cell Death Dis. 2020 Aug 20;11(8):664. doi: 10.1038/s41419-020-02895-y. (IF=9.0)

15. Li Dongping, Wang Ying, Jin Xinrong, Hu Die, Xia Chunlei, Hanmei Xu*. Hu Jialiang*. NK cell-derived exosomes carry miR-207 and alleviate depression-like symptoms in mice.[J]. J Neuroinflammation, 2020, Apr 22, 17: 126  sci：5.7. DOI:  10.1186/s12974-020-01787-4（IF=9.3）

16. Xinqiang Yin, Jialiang Hu, Hanmei Xu*. Distribution of micropeptide-coding sORFs in transcripts, Chinese Chemical Letters, 2018, 29(7):1029-1032.  DOI:  10.1016/j.cclet.2018.04.027 (IF:8.455)  

17. Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, Wang Y, Xue J, Qi, Sun Q, Zhang S, Hu J, Hanmei Xu*. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018, 11(1):102  DOI:  10.1186/s13045-018-0646-9 (IF= 28.5)

18. Erhao Zhang, Jieyi Gu and Hanmei Xu*. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer. 2018, 17(1):7. DOI:  10.1186/s12943-018-0759-3 (IF= 37.3) 

19. Lin C, Zhang S, Wang Y, Wang Y, Nice E, Guo C, Zhang E, Yu L, Li M, Liu C, Hu L, Hao J, Qi W, Hanmei Xu*. Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis. Clin Cancer Res. 2018, 24(2):486-498. DOI:  10.1158/1078-0432.ccr-17-1851  (IF= 11.5)

20. Zhang E, Gu J, Xue J, Lin C, Liu C, Li M, Hao J, Setrerrahmane S, Chi X, Qi W, Hu J*, Hanmei Xu*. Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide. J Hematol Oncol. 2018 Mar 20;11(1):44. doi: 10.1186/s13045-018-0591-7. (IF= 28.5) 

21. Li M, Han Y, Zhou H, Li X, Lin C, Zhang E, Chi X, Hu J, Hanmei Xu*. Transmembrane protein 170B is a novel breast tumorigenesis suppressor gene that inhibits the Wnt/β-catenin pathway. Cell Death Dis. 2018 Jan 24;9(2):91. DOI:  10.1038/s41419-017-0128-y (IF= 9.0) 

22. Setrerrahmane S, Hanmei Xu*, Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer. 2017 Sep 19;16(1):153. doi: 10.1186/s12943-017-0721-9. (IF= 37.3) 

23. Erhao Zhang, Hanmei Xu*. A new insight in chimeric antigen reeptor-engineered T cells for cancer immunotherapy. Journal of Hematology and Oncology, 2017,10:1-11.DOI:  10.1186/s13045-016-0379-6（IF= 28.5） 

24. C Zhao, J He, H Cheng, Z Zhu, Hanmei Xu*. Enhanced therapeutic effect of an antianiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA construct. Journal of Experimental & Clinical Cancer Research.2016, 35:107-117. DOI:  10.1186/s13046-016-0381-4  （IF=11.3）

1. Micropeptide/Microprotein Research: This research focuses on discovering pcRNA from ncRNA and identifying novel endogenous micropeptides/microproteins. The approach includes using gene bias, bioinformatics, multi-omics, and molecular and cellular biology to identify receptors and signaling pathways associated with micropeptides/microproteins, ultimately revealing their physiological and pathological activities and functions in vivo.

2. AI-Assisted Peptide Drug Research: By leveraging AI-assisted design, novel peptide molecules can be tailored to specific drug targets. This approach optimizes the affinity of these peptides (up to the nanomolar level) and supports the evaluation of their durability or the development of peptide conjugates.

3. CAR-T Research Using Peptides as Switches: This research involves designing bispecific CAR-T molecules and using peptides as switch molecules to regulate CAR-T activity. The goal is to reduce cytokine release, enabling precise treatment.

1. Award for Outstanding Contribution to Science and Technology in the 13th Five-Year Plan of China Pharmaceutical University in 2022;

2. First Prize of Technical Invention Award of Ministry of Education in 2019;

3. Second Prize of Jiangsu Pharmaceutical Science and Technology Progress Award in 2019;

4. Second Prize of China Industry-University-Research Cooperation Innovation Achievement Award in 2019;

5. First prize of China Invention Association in 2018;

6. First prize of Jiangsu Medicine Science and Technology Progress Award in 2014;

7. First prize of Jiangsu Provincial Science and Technology Award in 2011

1. Non-clinical Research and Development of New Drugs, Publication No.: 9787521419207

2. Antitumor Drug Pharmacology Laboratory Guide, Publication No.: 9787506778220

3. Enzyme Pharmacology, Publication No.: 9787506746960